Gilde Healthcare
en nl de
  • Portefeuille
  • Team
  • Nieuws
  • Over ons
  • Contact

Nieuws 2010

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Ascendis signs Global Agreement with Sanofi-aventis in Diabetes

21 december 2010 – Sanofi-aventis Acquires from Ascendis Pharma worldwide rights on Drug-Delivery Technology in Diabetes and Related Disorders – Innovative technology designed for sustained release of peptides and proteins – Paris, France – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Ascendis…

Gerelateerd aan: Ascendis Pharma

ABLYNX – Nanobody Candidate Selected by Boehringer Ingelheim for Development

8 december 2010 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected a Nanobody candidate for development. This is the first development candidate emerging from the strategic alliance which the companies entered into in 2007, and will result in…

Gerelateerd aan: Ablynx

Amsterdam Molecular Therapeutics Amends Amgen GDNF Gene License Agreement

2 december 2010 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the development of gene based therapies, today announced that it has amended and restated its licensing agreement with Amgen (Nasdaq: AMGN) for gene therapy applications incorporating…

Symphogen Receives Milestone Payment from Genentech for Antibody

30 november 2010 – COPENHAGEN, Denmark and PRINCETON, New Jersey - Symphogen A/S announced today that it has received an undisclosed milestone payment related to an antibody therapeutic in development under its ongoing collaboration with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX:…

Gerelateerd aan: Symphogen

mtm laboratories Extends Series C Financing Round by EUR 7 Million ($9.7 Million)

8 november 2010 – Heidelberg, Germany - mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its…

Gerelateerd aan: mtm laboratories

Gilde Healthcare Services investeert in woonzorgvilla's

25 oktober 2010 – Utrecht - Gilde Healthcare Services, een Nederlands groeikapitaalfonds gespecialiseerd in de gezondheidszorg, investeert in ouderenzorgbedrijf Stepping Stones Home & Care BV (Stepping Stones). Stepping Stones, gevestigd te Maarn, is een aanbieder van kleinschalige particuliere woonzorgvilla’s…

Gerelateerd aan: Stepping Stones

Amsterdam Molecular Therapeutics (AMT BV) successfully Lowers Cholesterol

25 oktober 2010 – AMSTERDAM - Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was…

Agendia Establishes Contract with Humana To Cover MammaPrint

19 oktober 2010 – IRVINE, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company’s MammaPrint test.  Agendia’s contract with Humana expands the…

Gerelateerd aan: Agendia

Ablynx enters second agreement with Merck Serono

13 oktober 2010 – Ablynx And Merck Serono Enter Into Second Agreement To Co-Discover And Co-Develop Nanobodies® GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that they have expanded their relationship and entered into a…

Gerelateerd aan: Ablynx

Amsterdam Molecular Therapeutics Successfully Raised € 14.3 m

6 oktober 2010 – Amsterdam – Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) announces today that it has successfully raised € 14.3 m in gross proceeds through a private placement of new shares with institutional investors, other qualifying investors who subscribed for at least…

Symphogen and Swedish Orphan Biovitrum receive U.S. orphan drug designation for Rozrolimupab in ITP

6 oktober 2010 – COPENHAGEN, Denmark and Stockholm, Sweden – Symphogen and Swedish Orphan Biovitrum (STO:SOBI)  today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to rozrolimupab (Sym001) for the treatment of primary Immune Thrombocytopenia…

Gerelateerd aan: Symphogen

Ablynx started a phase II study in TTP - in addition announces €3 million milestone payments

1 oktober 2010 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced that it has opened recruitment in its first clinical trial centre for an open-label, randomised Phase II study for patients with acquired thrombotic thrombocytopenic purpura (TTP). This Phase II study will be conducted in…

Gerelateerd aan: Ablynx

Pieris signs broad collaboration with Sanofi

28 september 2010 – Freising-Weihenstephan, Germany - Pieris AG announced the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which Pieris will apply its proprietary…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

Ascendis Pharma initiates Phase 2 clinical study of ACP-001, a once-weekly human growth hormone

16 september 2010 – Copenhagen, Denmark, September 16, 2010 – Ascendis Pharma A/S, a privately held specialty pharmaceutical company, announced that it has initiated a Phase 2 clinical study of ACP-001, a proprietary once-weekly human growth hormone prodrug. The Phase 2 clinical study will be conducted…

Gerelateerd aan: Ascendis Pharma

Acacia Pharma To Progress Two Projects For Nausea

6 september 2010 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces the initiation of two clinical development programmes: APD421 for the prevention and treatment of nausea & vomiting; and APD515 for the treatment…

Gerelateerd aan: Acacia Pharma

Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary

30 juli 2010 – Former Idun Management team to expand efforts in liver disease and oncology   SAN DIEGO - Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc.  Financial terms were not disclosed.  Conatus Pharmaceuticals is a privately-held…

Gerelateerd aan: Conatus Pharmaceuticals

SYMPHOGEN Issued United States Patent Covering Symplex Technology for Antibody Discovery

13 juli 2010 – COPENHAGEN, Denmark and PRINCETON, New Jersey - Symphogen A/S announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 7,749,697, titled "Method for linking sequences of interest." The patent broadly covers Symphogen's Symplex™ technology, a novel…

Gerelateerd aan: Symphogen

ABLYNX – Novartis Obtains Licenses to Develop and Commercialize Two Novel NANOBODIES®

12 juli 2010 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced today that Novartis has obtained licenses to further develop and commercialise Nanobodies against two complex targets. This has triggered a total of €1 million in upfront fees and license payments to Ablynx.   The two targets…

Gerelateerd aan: Ablynx

MTM Laboratories - p16 Immuno-cytochemistry shows superior clinical performance to HPV testing

21 juni 2010 – Large retrospective study in more than 800 cases now published in American Journal of Clinical Pathology Heidelberg, Germany – mtm laboratories, a fully integrated cancer diagnostics company with proprietary products marketed globally, today announced the publication of a large study…

Gerelateerd aan: mtm laboratories

PROFIBRIX and CSL Behring Enter into Fibrinogen and Thrombin Supply Agreement

17 juni 2010 – LEIDEN, THE NETHERLANDS and SEATTLE, WA - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced that it has entered into an agreement with CSL Behring for the clinical and commercial supply of plasma-based fibrinogen…

Gerelateerd aan: ProFibrix

Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound

15 juni 2010 – Anti-VEGF PRS-050 is first Anticalin tested in humans Freising-Weihenstephan, Germany - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin.  The trial is an open-label, dose-escalating evaluation…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

Pieris AG Appoints Chief Scientific Officer

7 juni 2010 – Freising-Weihenstephan - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

mtm’s CINtec® PLUS, delivers new solution to manage Pap negative but HPV positive women

27 mei 2010 – Study results presented at EFC Congress, Berlin 27-29 May 2010 Heidelberg, Germany - mtm laboratories today announced the results of a study that showed dual staining for p16 and Ki-67 in a single test was capable of identifying the underlying cases with high-grade disease among…

Gerelateerd aan: mtm laboratories

ABLYNX - NANOBODY® Lead Candidate Selected by Boehringer Ingelheim

24 mei 2010 – GHENT, Belgium -Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for the treatment of Alzheimer's disease. This is the first lead candidate emerging from the Alzheimer's disease collaboration…

Gerelateerd aan: Ablynx

Gilde Healthcare II sells its stake in FlowCardia

17 mei 2010 – US-based Medtech portfolio company FlowCardia Inc acquired by C.R. Bard Utrecht, The Netherlands – Gilde Healthcare Partners, an investor in Healthcare Technologies and Services, announces the sale of its portfolio company FlowCardia, Inc. to C.R. Bard for a total amount of approximately…

Gerelateerd aan: Flowcardia

PIERIS Announces Positive Preclinical Data on c-Met Anticalin Drug Program

30 april 2010 – Freising-Weihenstephan, Germany - Pieris AG announced preclinical data for its proprietary PRS-110 Anticalin® compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model. The results provide an indication that an…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

SANTARIS PHARMA advances RNA-targeted drug development candidate against PCSK9

26 april 2010 – Santaris Pharma A/S selects lead research compound SPC5001 targeting PCSK9 to advance into drug development for the treatment of high cholesterol PCSK9, an important new target, is a protein involved in regulating LDL or “bad” cholesterol in the blood– a major risk factor for coronary…

Gerelateerd aan: Santaris Pharma

Inverness Medical and BG MEDICINE to Develop Galectin-3 Test for Inverness’ Triage® Meter

26 april 2010 – Waltham, MA—BG Medicine, Inc. announced today that it has entered into an agreement with Inverness Medical Innovations, Inc. (NYSE: IMA)—a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management—for…

Gerelateerd aan: BG Medicine

SYMPHOGEN - Sympress II Production System Enables Antibody Manufacturing

26 april 2010 – Company demonstrates ability to manufacture for large therapeutic markets COPENHAGEN, Denmark and PRINCETON, New Jersey - Symphogen A/S today announced the publication of data in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al. [epub ahead of print]…

Gerelateerd aan: Symphogen

AGENDIA and Ferrer inCode Expand MammaPrint(r) Distribution Agreement to Latin America

20 april 2010 – HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today it has closed an agreement with Ferrer inCode for the commercialization of Agendia’s FDA-cleared breast cancer recurrence test MammaPrint in Latin America. …

Gerelateerd aan: Agendia

SYMPHOGEN Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors

1 april 2010 – Copenhagen, Denmark and PRINCETON, New Jersey - Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed…

Gerelateerd aan: Symphogen

ABLYNX Selects a Novel Pre-Clinical Development Candidate for Administration via Pulmonary Delivery

26 maart 2010 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced today that it has advanced ALX-0171, a new Nanobody®-based therapeutic programme, into pre-clinical development for the treatment of respiratory synctial virus (RSV) infections. ALX-0171 is a Nanobody product which binds…

Gerelateerd aan: Ablynx

AGENDIA to Play Pivotal Role in ISPY-2 Trial for Breast Cancer, 12 Cancer Drugs Tested

17 maart 2010 – HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites. I-SPY 2 is an…

Gerelateerd aan: Agendia

Ablynx successfully raises €50 million with Secondary Public Offering

15 maart 2010 – GHENT, Belgium - Ablynx, the biopharmaceutical company focused on the discovery and development of Nanobodies®, announced that it has successfully completed its Secondary Public Offering (the "SPO" or "Offering") raising €50 million. The offered shares were priced at €7.5 per share.…

Gerelateerd aan: Ablynx

ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM)

11 maart 2010 – LEIDEN, THE NETHERLANDS and SEATTLE, WA - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps. Promising preliminary data from…

Gerelateerd aan: ProFibrix

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

10 maart 2010 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously…

mtm laboratories Announces the European Launch of CINtec(R) PLUS

8 maart 2010 – Powerful new biomarker combination for cervical cancer screening  mtm laboratories, a privately held diagnostics company today announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management…

Gerelateerd aan: mtm laboratories

BG Medicine and Abbott to Develop Galectin-3 Test for the i-STAT® System

8 maart 2010 – Waltham, MA—BG Medicine, Inc. today announced that it has entered into an agreement with Abbott Laboratories (NYSE: ABT) to extend its current development and commercialization collaboration to include the development of a galectin-3 test for Abbott Point of Care’s i-STAT System.…

Gerelateerd aan: BG Medicine

ABLYNX Receives EUR 1.2 Million Grant to Further Advance its Anti-IL-6R Programme, ALX-0061

19 februari 2010 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], announced today that it has been awarded a grant worth €1.2 million by the Flemish agency for Innovation by Science and Technology (IWT).   The grant supports Ablynx in accelerating the development of its Nanobody-based programme,…

Gerelateerd aan: Ablynx

MTM LABORATORIES - CINtec® p16 Histology test increases accuracy in diagnosing

16 februari 2010 – Results Published in the American Journal of Clinical Pathology Heidelberg, Germany - mtm laboratories, a privately held diagnostics company, today announced the publication of new research showing that CINtec Histology p16 immunostaining significantly increased the accuracy for…

Gerelateerd aan: mtm laboratories

ABLYNX Win Patent Opposition Case

11 februari 2010 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has been successful in the opposition that it had filed in 2007 against the European Patent 1 517 921, which was granted in 2006 to Domantis (now a member of the GlaxoSmithKline group of companies). As a result,…

Gerelateerd aan: Ablynx

ABLYNX Selects GPCR Targeting Development Candidate and Announces New Data on Alternative Routes

11 februari 2010 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced today that it has selected a new GPCR targeting development candidate, ALX-0651, an anti-CXCR4 Nanobody which is being developed for hematopoietic stem cell mobilisation. The Company is also releasing new data on pulmonary…

Gerelateerd aan: Ablynx

FlowCardia, Inc. Initiates CENTRAL Study Enrollment

9 februari 2010 – Study designed to confirm CROSSER® Catheter routinely navigates through the central lumen of SFA chronic total occlusions Sunnyvale, CA – FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced…

Gerelateerd aan: Flowcardia

BG MEDICINE files Registration Statement for proposed Initial Public Offering at NASDAQ

29 januari 2010 – Waltham, MA — BG Medicine, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range of…

Gerelateerd aan: BG Medicine

BG Medicine Announces Receipt Of CE Mark For Its Galectin-3 Blood Test

28 januari 2010 – BG Medicine, Inc., a privately-held developer of biomarker-based in vitro diagnostics, announced the commercial launch in the European Union of a new, CE-marked test for the measurement of galectin-3 in human plasma or serum. Galectin-3 was first shown by researchers at the University…

Gerelateerd aan: BG Medicine

Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy

11 januari 2010 – Novel mechanism of action resulted in superior anticancer effects vs ERBITUX® and Vectibix® Sym004 advancing into the clinic Results further validate Symphogen’s proprietary discovery  platforms to identify potential antibody therapeutics for serious diseases COPENHAGEN, Denmark…

Gerelateerd aan: Symphogen

AMT submits its lead product Glybera® Application for Marketing Authorisation Application to EMA

11 januari 2010 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Marketing Authorisation Application (MAA) for Glybera®, AMT’s proprietary lead product, for lipoprotein lipase deficient patients, has…

Amsterdam Molecular Therapeutics receives € 4 million Innovation Credit

6 januari 2010 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it will receive an Innovation Credit of up to € 4 million from the Dutch government to support the development of AMT’s gene therapy treatment…

Pieris Appoints a New CEO

4 januari 2010 – Appointment will bring substantial deal-making expertise to the company Freising-Weihenstephan, Germany – Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect.  Mr. Yoder takes over the position from interim CEO and co-founder Claus Schalper,…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is een gespecialiseerde Europese investeringsmaatschappij met €1.4 miljard ($1.5 miljard) onder beheer in twee aparte fondsstrategieën: venture & groeikapitaal en private equity. Gilde Healthcare's venture & groeikapitaalfonds participeert in medische technologie en nieuwe geneesmiddelen. De venture & groeibedrijven zijn gevestigd in Europa en Noord Amerika. Gilde Healthcare’s private equity fonds neemt deel in winstgevende Europese bedrijven met een primaire focus op de middenmarkt in Benelux en Duitstalige landen. Het private equity fonds is gericht op zorgverleners, toeleveranciers en producenten van medische producten en overige dienstverleners actief in de zorgsector.

Investeringsfilosofie

Gilde Healthcare investeert in snelgroeiende, innovatieve bedrijven die betere zorg tegen lagere kosten mogelijk maken.

  • Home
  • Portefeuille
  • Team
  • Nieuws
  • Contact
  • Imprint
  • Privacy Policy